Abstract Number: 2729 • 2015 ACR/ARHP Annual Meeting
Clinical and Radiographic Outcome of Iguratimod for Rheumatoid Arthritis
Background/Purpose: Iguratimod is a new small-molecular drug for rheumatoid arthritis (RA), which was approved on June, 2012 in Japan. The agent inhibits the production of…Abstract Number: 2730 • 2015 ACR/ARHP Annual Meeting
Patient-Reported Outcomes from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis with Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs
Background/Purpose: Baricitinib (bari) is an oral Janus kinase (JAK) 1 /JAK2 selective inhibitor, representing a potentially effective treatment for patients with moderately to severely active rheumatoid…Abstract Number: 2731 • 2015 ACR/ARHP Annual Meeting
Persistency of Tocilizumab As Monotherapy or Combination Therapy in Patients with Rheumatoid Arthritis–Real-World Analyses from the US Corrona Registry
Background/Purpose: For patients with rheumatoid arthritis (RA), there are limited real-world data on factors that predict persistency on biologic therapy or whether use of biologics…Abstract Number: 2732 • 2015 ACR/ARHP Annual Meeting
The Effect of Adrenocorticotropin Gel (HP Acthar Gel) in Combination with MTX in Newly Diagnosed RA Patients from a Clinical and Structural Perspective
Background/Purpose: Although adrenocorticotropin (ACTH) gel was approved by the FDA for the treatment of RA in 1952, data on its clinical and structural benefits for…Abstract Number: 2733 • 2015 ACR/ARHP Annual Meeting
Effect of Abatacept on Telomerase Activity of Lymphocytes of Patients with Rheumatoid Arthritis
Background/Purpose: Telomere is a component of chromosome, and protects end of chromosome from various stress. Telomere shortens during cell division, and telomerase maintains telomere length.…Abstract Number: 2734 • 2015 ACR/ARHP Annual Meeting
Validation and Comparison Study of Immunoassays for the Measurement of Golimumab and Antibodies to Golimumab in Rheumatic Patients
Background/Purpose: The options for treatment of rheumatoid arthritis (RA) with tumour necrosis factor (TNF) inhibitors is constantly growing. As a consequence monitoring of drug levels (DL)…Abstract Number: 2735 • 2015 ACR/ARHP Annual Meeting
Is Disease Duration an Independent Predictor of Treatment Response Among Patients with Rheumatoid Arthritis Initiating Abatacept?
Background/Purpose: It has been postulated that patients with longstanding RA have more treatment-resistant disease. We propose to examine whether disease duration is an independent predictor…Abstract Number: 2736 • 2015 ACR/ARHP Annual Meeting
Reduction of Disease Burden on Workplace and Household Productivity Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in DMARD-Naïve Patients with Active, Severe, Progressive Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is associated with work disability and lower employment rates (evidence shows 20–30% of pts are work disabled in the first 3…Abstract Number: 2737 • 2015 ACR/ARHP Annual Meeting
Consistency of Treatment Effects Across Different High-Risk Clinical Phenotypes in the Tofacitinib Clinical Program
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Patients (pts) with RA often have comorbidities that may affect treatment response.…Abstract Number: 2738 • 2015 ACR/ARHP Annual Meeting
A Comparison of EQ5D Index from the UK, US, and Japan Preference Weights Model, and Mapping Algorithm from Clinical Outcomes in Patients with Rheumatoid Arthritis: Results from Golimumab Intravenous Study
Background/Purpose: To compare the EQ5D index from the UK, US, and Japan preference weights models in patients with rheumatoid arthritis (RA), and to examine the…Abstract Number: 2739 • 2015 ACR/ARHP Annual Meeting
Survival of Etanercept (ETN) Responders after Methotrexate (MTX) Failure When ETN Is Initiated As Mono or Combination Therapy or after MTX Withdrawal from ETN/MTX Combination in Long Standing Rheumatoid Arthritis (RA). a Single Center Retrospective Study
Background/Purpose: The long term sustainability of ETN as monotherapy (mono) or in combination (combo) with methotrexate (MTX) is uncertain in patients with longstanding RA responding…Abstract Number: 2740 • 2015 ACR/ARHP Annual Meeting
ACPA Positivity in the Elderly and Concomitant MTX Use in Younger May be Useful Predictive Factors for Superior Clinical Efficacy with Abatacept in Japanese Biological-Naïve RA Patients
Background/Purpose: Sustained clinical remission is crucial in the RA. However, baseline predicting factors for sustained clinical remission in RA patients treated with abatacept (ABT) are…Abstract Number: 2741 • 2015 ACR/ARHP Annual Meeting
An Analysis of the Efficacy of Tofacitinib Monotherapy in MTX-Naïve Patients with Early RA Compared with Patients with Established RA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. In a Phase 3 study (ORAL Start; NCT01039688), tofacitinib monotherapy in MTX-naïve…Abstract Number: 2742 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib Monotherapy Versus Combination Therapy in a Latin American Subpopulation of Patients with Rheumatoid Arthritis: A Pooled Phase 3 Analysis
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post-hoc pooled analysis was designed to assess the efficacy and safety…Abstract Number: 2743 • 2015 ACR/ARHP Annual Meeting
Treatment Target Status at 6 Months and Long-Term Outcomes at 5 Years: Analysis of Methotrexate-Naïve Patients with Rheumatoid Arthritis
Background/Purpose: Management guidelines recommend patients (pts) with RA should be treated with the intent of reaching a clinical target of low disease activity or remission…
ACR Meeting Abstracts